Trials / Unknown
UnknownNCT06160362
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Relapse and Refractory Patients With CD19+/CD20+ Non-Hodgkin's Lymphoma (NHL)
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a study for patients who have been previously treated for NHL. The purpose of this study is to determine the safety and feasibility of double-target CART-19 and 20 cells to the patients with relapsed and refractory CD19+/CD20+ NHL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CART-19 and 20 cells | Double-target CART-19 and 20 cells will be administered on day0 after completion of the chemotherapy. |
| DRUG | Cyclophosphamide | patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2). |
| DRUG | Fludarabine | Fludarabine 25mg/m2/day IV for 3 days (Day-4 to day-2). |
Timeline
- Start date
- 2023-10-31
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2023-12-07
- Last updated
- 2023-12-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06160362. Inclusion in this directory is not an endorsement.